IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
A month after landing Canadian approval for its updated neuromodulation implant to treat incontinence, Axonics is bringing the fourth-generation R20 device across the border. The FDA has approved the ...
Axonics rechargeable implantable sacral neurostimulator. The FDA has approved a new version of Axonics Modulation’s rechargeable implantable sacral neurostimulator (r-SNM) system that allows patients ...
In 2020, hot on the heels of Axonics Modulation Technologies’ FDA approval for a rechargeable neuromodulation implant to treat urinary and bowel dysfunction, Medtronic scored a regulatory win of its ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...
Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results